Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors
Status:
Completed
Trial end date:
2019-06-27
Target enrollment:
Participant gender:
Summary
To compare the impact of insulin degludec (IDeg-100) and insulin glargine U300 (IGlar-300) on
cardiovascular risk parameters - glycaemic variability (GV), oxidative stress, arterial
stiffness and lipid parameters - in insulin naive patients with DMT2.
Phase:
Phase 4
Details
Lead Sponsor:
University of Split, School of Medicine
Collaborators:
Ana Šešelja Perišin Božo Smajić Darko Modun Doris Rušić Gordan Kardum Jonatan Vuković Josipa Bukić Pavle Vrebalov Cindro Tina Tičinović Kurir